Clinical Trial Detail

NCT ID NCT01272037
Title Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

Therapies

Anastrozole

Letrozole

Tamoxifen

Exemestane

Age Groups: adult

Additional content available in CKB BOOST